• LAST PRICE
    1.3600
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    1.2200/ 10
  • Ask / Lots
    1.4000/ 5
  • Open / Previous Close
    0.0000 / 1.3600
  • Day Range
    ---
  • 52 Week Range
    Low 0.8503
    High 2.6500
  • Volume
    5
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
Table Data Not Available
Data delayed at least 15 minutes.
No documents available
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesXTLB
X T L Biopharmaceuticals Ltd
7.1M
-2.4x
---
United StatesCPMV
Mosaic Immunoengineering Inc
7.2M
-2.7x
---
United StatesQNRX
Quoin Pharmaceuticals Ltd
7.3M
0.0x
---
United StatesPHIO
Phio Pharmaceuticals Corp
6.9M
-7.6x
---
United StatesHILS
Hillstream BioPharma Inc
6.9M
-1.4x
---
United StatesATXI
Avenue Therapeutics Inc
7.5M
-0.4x
---
As of 2023-01-26

Company Information

XTL Biopharmaceuticals Ltd is a biopharmaceutical company engaged in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. The Company pipelines include hCDR1 systematic lupus erythematosus and recombinant human erythropoietin (rHuEPO) multiple myeloma. Its hCDR1, which is a potential treatment for systemic lupus erythematosus (SLE) and Sjogren’s syndrome (SS). hCDR1 is a peptide (short protein) that is administered subcutaneously and acts as a disease-specific treatment to modify the SLE-related autoimmune process. The rHuEPO known agent for anemia to prolong the survival of patients for the treatment of multiple myeloma blood cancer. Its Erythropoietin (EPO) is a glycoprotein hormone produced mainly by the kidney. EPO stimulates erythropoiesis, the production of red blood cells, by binding to its receptor on the surface of erythroid progenitor cells, promoting their proliferation and differentiation and maintaining their viability.

Contact Information

Headquarters
5 Badner St., P.O.Box 8241RAMAT GAN, NY, Israel 5218102
Phone
---
Fax
---

Executives

Chairman of the Board, Chief Executive Officer
Doron Turgeman
Chief Executive Officer, Director
Shlomo Shalev
Chief Financial Officer
Itay Weinstein
Non-Executive Director
Dobroslav Melamed
Non-Executive Director
Alexander Rabinovitch

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$7.1M
Revenue (TTM)
$0.00
Shares Outstanding
5.4M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.31
EPS
$-0.58
Book Value
$9.79
P/E Ratio
-2.4x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.